ACET - NASDAQ

Adicet Bio, Inc.

ACET·NASDAQ

$8.15

+4.1%

HealthcareBiotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$76.19M

EPS-16.9500

P/E Ratio-0.48

Earnings Date08/06/2026

acet

Selling, General and Administrative Expenses

Last Annual Value

22.99M

3-Year CAGR

-4%

5-Year CAGR

10-Year CAGR

-10%

Adjust for Inflation

Adicet Bio, Inc. Competitors Analysis of Selling, General and Administrative Expenses

ACET · NASDAQ

Company	Selling, General and Administrative Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Adicet Bio, Inc. NASDAQ:ACET	22.99M	-4.7%	0.7%	173.0%
Gain Therapeutics, Inc. NASDAQ:GANX	8.50M	-7.6%	4.4%	N/A
Lite Strategy, Inc. NASDAQ:LITS	13.53M	-25.8%	-11.1%	N/A
Adverum Biotechnologies, Inc. NASDAQ:ADVM	63.12M	4.7%	-0.4%	10.0%
ALX Oncology Holdings Inc. NASDAQ:ALXO	23.85M	-5.7%	0.4%	N/A
Fractyl Health, Inc. Common Stock NASDAQ:GUTS	21.15M	N/A	15.0%	N/A
ImageneBio Inc NASDAQ:IMA	20.73M	-6.0%	2.8%	N/A
Pliant Therapeutics, Inc. NASDAQ:PLRX	47.22M	-6.6%	11.4%	N/A
Shattuck Labs, Inc. NASDAQ:STTK	17.23M	-3.7%	-1.6%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	31.99M	7.9%	18.3%	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	24.12M	4.4%	57.8%	N/A

Adicet Bio, Inc. Fair Value Envelope

ACET · NASDAQ

Our analysis suggests that ACET has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.15, this represents a potential HIDDEN relative to our calculated worth for Adicet Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.15

Related Guides

Blog Categories

Continue your ACET research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.